Severe Tricuspid Regurgitation Clinical Trial
Official title:
International Multisite Transcatheter Tricuspid Valve Therapies Registry
For a long time, tricuspid valve disease has been considered as less important than
left-sided valvular heart disease. If treated in an advanced stage and simultaneously with
other cardiac diseases, it is associated with significant morbidity and mortality. Hence,
physicians tend to refer patients more aggressively to surgery (1).
Transcatheter procedures are an attractive alternative in high-risk patients. The field of
transcatheter tricuspid devices has rapidly advanced over the last few years (2). Limited
knowledge is available regarding the epidemiologic and anatomical settings in which these
therapies are preferentially applied.
The main purpose of this registry is the collection of baseline clinical and anatomical data
of the patients treated with transcatheter tricuspid valve therapies, and their outcomes,
whenever feasible. Apart from more knowledge regarding the current status in this field, the
results could also help the establishment of guidelines with respect to the choice of the
transcatheter device selected and to understand which therapy can provide the better outcome
in the different anatomies. Moreover, this study will provide important information about the
epidemiology of severe tricuspid regurgitation, which is at the moment an undertreated
disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03723239 -
TRICUS STUDY - Safety and Efficacy of the TricValve® Device
|
N/A | |
| Terminated |
NCT02387697 -
Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)
|
Phase 2/Phase 3 | |
| Completed |
NCT04141137 -
TRICUS STUDY Euro - Safety and Efficacy of the TricValve® Device
|
N/A |